# The KHENEREXT Study

> **NCT04604548** · PHASE2 · COMPLETED · sponsor: **Khondrion BV** · enrollment: 11 (actual)

## Conditions studied

- Mitochondrial Diseases
- Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
- Maternally Inherited Diabetes and Deafness (MIDD)
- Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke Like Episodes (MELAS)
- Chronic Progressive External Ophthalmoplegia (CPEO)

## Interventions

- **DRUG:** Oral administration of 100 mg KH176 twice daily

## Key facts

- **NCT ID:** NCT04604548
- **Lead sponsor:** Khondrion BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-09
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2024-03-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04604548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04604548, "The KHENEREXT Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04604548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*